Pharmaceutical Technology
APRIL 28, 2023
Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a sales growth of 23% in 2023. In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029.
pharmaphorum
OCTOBER 26, 2022
The first patient has already been enrolled into its FIBRONEER phase 3 programme for BI 1015550, which already has a breakthrough designation from the FDA after a positive phase 2 trial showed improved lung function in patients with IPF over a 12-week period. There are more than 200 lung disorders that can lead to pulmonary fibrosis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 10, 2023
Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D. billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%.
European Pharmaceutical Review
OCTOBER 26, 2023
Yet as the market continues to recognise the value of these treatments, especially with them having “clear benefits over current monotherapy and combination therapy options in cancer treatment”, it is unsurprising that GlobalData’s research predicted the ADC oncology therapy market will value more than $36 billion by 2029.
Pharmaceutical Technology
FEBRUARY 3, 2023
However, after almost seven years of staving off competitors through patents and litigation, Humira’s market-leading position in the US will be affected as Amgen’s adalimumab biosimilar, Amjevita, started to roll out on January 31, 2023. billion in 2022.
Pharmaceutical Technology
APRIL 4, 2023
of NSCLC patients with exon 19 and 21 mutations develop resistance mutations at C797S. While Scorpion will lead the development of STX-721, Pierre Fabre will handle STX-241. billion in 2029. Up to 12.5% Scorpion received a $65 million upfront payment, with the potential to earn up to $553 million in milestones.
pharmaphorum
DECEMBER 20, 2022
Wedbush Securities recently forecast more than $1 billion in 2029 sales for ensifentrine in the US alone, assuming a launch in the first quarter of 2024, and said today the stock could easily reach $30. COPD is the third leading cause of death worldwide, with 3.23 and drive the company’s market cap to almost $1.5
Expert insights. Personalized for you.
52 
Let's personalize your content